Table 4.
Perfusion and spectral parameters in the different WHO pathological subtypes of 51 TETs.
| Perfusion, Spectral parameters | WHO pathological subtypes | ||||||
|---|---|---|---|---|---|---|---|
| Type A (n = 4) | Type AB (n = 5) | Type B1 (n = 7) | Type B2 (n = 10) | Type B3 (n = 8) | TC (n = 17) | P | |
| BF(ml/min/100 g) | 169.66 ± 18.08 | 145.38 ± 12.37 | 57.94 ± 20.30 | 71.47 ± 20.49 | 45.46 ± 8.34 | 53.62 ± 13.84 | <0.001 |
| BV(ml/100 g) | 26.60 ± 11.37 | 15.98 ± 4.16 | 6.74 ± 3.02 | 6.61 ± 1.76 | 5.16 ± 0.92 | 6.21 ± 1.89 | <0.001 |
| MTT(s) | 11.27 ± 3.88 | 8.51 ± 1.71 | 8.90 ± 1.40 | 7.27 ± 1.40 | 9.88 ± 2.45 | 9.86 ± 4.07 | 0.134 |
| PS(ml/min/100 g) | 36.79 ± 10.31 | 35.06 ± 7.76 | 15.15 ± 7.67 | 23.28 ± 10.99 | 21.40 ± 7.11 | 28.92 ± 11.68 | 0.004 |
| WCa(mg/cm3) | 1038.62 ± 4.03 | 1032.95 ± 0.95 | 1040.18 ± 1.38 | 1034.47 ± 6.13 | 1032.86 ± 3.20 | 1034.78 ± 5.55 | 0.070 |
| ICa (×102 μg/cm3) | 38.45 ± 5.34 | 29.38 ± 1.43 | 9.01 ± 0.59 | 6.60 ± 2.23 | 8.85 ± 2.33 | 12.35 ± 4.94 | <0.001 |
| NICa | 0.244 ± 0.034 | 0.157 ± 0.006 | 0.083 ± 0.006 | 0.060 ± 0.021 | 0.063 ± 0.011 | 0.090 ± 0.029 | <0.001 |
| λHUa | 5.48 ± 0.49 | 4.76 ± 0.17 | 1.44 ± 0.09 | 1.03 ± 0.32 | 1.41 ± 0.33 | 1.91 ± 0.74 | <0.001 |
| WCv(mg/cm3) | 1027.17 ± 4.42 | 1036.30 ± 1.68 | 1037.31 ± 4.72 | 1028.74 ± 9.55 | 1037.35 ± 6.48 | 1034.34 ± 5.93 | 0.054 |
| ICv(×102 μg/cm3) | 36.19 ± 2.30 | 25.28 ± 0.46 | 9.35 ± 0.58 | 8.18 ± 1.10 | 10.88 ± 3.21 | 13.72 ± 3.44 | <0.001 |
| NICv | 0.597 ± 0.038 | 0.410 ± 0.008 | 0.248 ± 0.029 | 0.190 ± 0.029 | 0.280 ± 0.054 | 0.368 ± 0.170 | <0.001 |
| λHUv | 5.41 ± 0.56 | 3.82 ± 0.07 | 1.48 ± 0.11 | 1.27 ± 0.17 | 1.69 ± 0.46 | 2.18 ± 0.54 | <0.001 |
BF, blood flow; BV, blood volume; MTT, mean transit time; PS, permeability surface.
WC, water concentration; IC iodine concentration; NIC, normalized iodine concentration; λHU, slope of spectral HU curve.
a, the optimal arterial phase; v, the optimal venous phase.
TC, thymic carcinoma.